Parliamentary QA
Prescription Costs for Evrysdi for Spinal Muscular Atrophy
22 March 2023
This article has been migrated from an earlier version of the site and may display formatting inconsistencies.
NOTICE PAPER NO. 1805
NOTICE OF QUESTION FOR WRITTEN ANSWER
FOR THE SITTING OF PARLIAMENT ON OR AFTER 22 MARCH 2023
Name and Constituency of Member of Parliament
Mr Chua Kheng Wee Louis
MP for Sengkang
Question No. 2831
To ask the Minister for Health (a) what is the breakdown of the yearly prescription costs for Evrysdi for the treatment of spinal muscular atrophy in Singapore; (b) what is the range of prices charged for Evrysdi in countries where the use of the drug is approved; and (c) what is the mechanism by which the pricing of such drugs is regulated in Singapore.
Answer
1 The drug risdiplam, sold under the brand name Evrysdi, is an oral medicine registered with HSA for the treatment of spinal muscular atrophy (SMA).
2 The average yearly cost of risdiplam in Singapore is about S$375,000, compared to published prices ranging from S$260,000 to S$390,000 in some countries.
3 MOH does not regulate drug prices in private hospitals. However, for public health institutions, the Agency for Care Effectiveness (ACE) conducts value-based pricing negotiations with pharmaceutical companies, to ensure that prices are commensurate with the outcomes they deliver for patients, and PHIs’ charges would cover some operations and overheads costs.